These trials completed more than 12 months ago and should have reported results. Some have, some have not.
These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.
These trials have problematic data on the registry. Details why »
|Status||Trial ID||Title||Completion date||Category|
|Not reported||2007-004779-21||A Randomized, Parallel-Group, Phase 2 Dose-finding Study to Evaluate the Effects of BA058 in the Treatment of Postmenopausal Women with Osteoporosis||2008-11-20||due-trials|
|Not reported||2010-022576-30||A Randomized, Double-blind, Placebo-controlled, Comparative Phase 3 Multicenter Study to Evaluate the Safety and Efficacy of BA058 for Injection for Prevention of Fracture in Ambulatory Postmenopausal...||2014-10-07||due-trials|
|Not reported||2012-001921-29||A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of BA058 Administered via a Coated Transdermal Microarray Delivery System (BA058 Transdermal) in Healthy Postmenopausal Women with Osteopo...||2013-09-13||due-trials|
|Not reported||2012-002216-10||An Extension Study to Evaluate 24 Months of Standard-of-Care Osteoporosis Management Following Completion of 18 Months of BA058 or Placebo Treatment in Protocol BA058-05-003||2016-10-03||due-trials|
|Ongoing||2017-004220-30||A Randomized, Double blind, Placebo controlled, Phase 3 Multicenter Study to Evaluate the Safety and Efficacy of Abaloparatide SC for the Treatment of Men with Osteoporosis.||not-yet-due|
|Ongoing||2018-002990-24||Elacestrant Monotherapy vs. Standard of Care for the Treatment of Patients with ER+/HER2- Advanced Breast Cancer Following CDK4/6 Inhibitor Therapy: A Phase 3 Randomized, Open-Label, Active-Controlled...||not-yet-due|